{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001743","form_type":"8-K","ticker":null,"cik":"0001844280","company_name":"Thorne Healthtech, Inc.","filed_at":"2023-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.081643+00:00","generated_at":"2026-06-20T01:18:22.859265+00:00","sec_items":["1.01","2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Thorne HealthTech acquires PreCon Health for $5M cash to bolster brain health portfolio","bullets":["Acquired all outstanding shares of PreCon Health on Jan 31, 2023, for $5.0M in cash.","Deal provides access to PreCon's brain health products, IP, and top-tier Medical and Scientific Advisory Board.","Thorne and PreCon previously partnered in 2021 to launch SynaQuell and SynaQuell+ supplements.","Thorne may pay future royalties to Eigenlyfe on certain supplement sales upon meeting profit criteria.","Ongoing Mayo Clinic clinical trials (NCT05041192, NCT05498818) study SynaQuell's effect on brain function."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001743","json":"https://secwatch.observer/filing/0000950170-23-001743.json","markdown":"https://secwatch.observer/filing/0000950170-23-001743.md","text":"https://secwatch.observer/filing/0000950170-23-001743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844280/000095017023001743/0000950170-23-001743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844280/000095017023001743/thrn-20230131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T01:18:22.859265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e001828d3d27281ed06a757182cf944b5794506d","claim":"Thorne Healthtech, Inc. completed an acquisition involving PreCon Acquisition LLC for $5.0 million in cash (closed 2023-01-31).","evidence_excerpt":"(the “Purchase Agreement”) with PreCon Acquisition LLC, the holder of the Shares and Eigenlyfe LLC (“Eigenlyfe”). Thorne acquired the Shares for an aggregate purchase price of $5.0 million in cash. Thorne will also be obligated to pay royalties to Eigenlyfe on sales of certain nutritional supplements upon achieving certain profit criteria, as described in the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844280/000095017023001743/0000950170-23-001743-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"PreCon Acquisition LLC"},{"label":"Consideration","value":"$5.0 million in cash"},{"label":"Closing","value":"2023-01-31"}],"fact_type":"ma_transaction"},{"claim_id":"d1372a86cb98c95bb5c77bf43e6c091867d6ac5c","claim":"Thorne Healthtech, Inc. entered into Purchase Agreement with PreCon Acquisition LLC and Eigenlyfe LLC valued at $5.0 million (effective 2023-01-31).","evidence_excerpt":"On January 31, 2023, Thorne HealthTech, Inc. (“Thorne”, or the “Company”), acquired all of the outstanding shares (the “Shares”) of PreCon Health, Inc., a Delaware corporation (“PreCon”), pursuant to a stock purchase agreement (the “Purchase Agreement”) with PreCon Acquisition LLC, the holder of the Shares and Eigenlyfe LLC (“Eigenlyfe”). Thorne acquired the Shares for an aggregate purchase price of $5.0 million in cash.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844280/000095017023001743/0000950170-23-001743-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"PreCon Acquisition LLC and Eigenlyfe LLC"},{"label":"Value","value":"$5.0 million"},{"label":"Effective","value":"2023-01-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}